Glenmede Trust CO Na Alaunos Therapeutics, Inc. Transaction History

Glenmede Trust CO Na

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.41 - $1.24 $248 - $751	-606 Reduced 2.94%	20,000 $24,000
Q3 2021 Nov 15, 2021	BUY	$1.44 - $2.73 $872 - $1,654	606 Added 3.03%	20,606 $37,000
Q2 2021 Aug 16, 2021	BUY	$2.63 - $3.67 $52,600 - $73,400	20,000 New	20,000 $52,000
Q3 2020 Nov 16, 2020	SELL	$2.39 - $3.43 $2,151 - $3,087	-900 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$2.2 - $3.71 $1,980 - $3,339	900 New	900 $2,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $424M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.